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Abstract
Deregulation of c-Myc (Myc) occurs in many cancers. In addition to transforming various cell types, Myc also influences
additional transformation-associated cellular phenotypes including proliferation, survival, genomic instability, reactive
oxygen species production, and metabolism. Although Myc is wild type in most cancers (wtMyc), it occasionally acquires
point mutations in certain lymphomas. Some of these mutations confer a survival advantage despite partially attenuating
proliferation and transformation. Here, we have evaluated four naturally-occurring or synthetic point mutations of Myc for
their ability to affect these phenotypes, as well as to promote genomic instability, to generate reactive oxygen species and
to up-regulate aerobic glycolysis and oxidative phosphorylation. Our findings indicate that many of these phenotypes are
genetically and functionally independent of one another and are not necessary for transformation. Specifically, the higher
rate of glucose metabolism known to be associated with wtMyc deregulation was found to be independent of
transformation. One mutation (Q131R) was greatly impaired for nearly all of the studied Myc phenotypes, yet was able to
retain some ability to transform. These findings indicate that, while the Myc phenotypes examined here make additive
contributions to transformation, none, with the possible exception of increased reliance on extracellular glutamine for
survival, are necessary for achieving this state.
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Introduction
Deregulation of the c-Myc oncoprotein (hereafter Myc) occurs
in many human cancers, generally as a consequence of MYC gene
amplification or its aberrant transcriptional regulation [1]. In
certain lymphomas, Myc over-expression results from a chromo-
somal translocation of MYC into an immunoglobulin gene locus,
which suffices to drive the high-level expression of the proto-
oncogene in the pre-B or B cell environment [1,2].
Although the Myc protein sequence remains unaltered in most
cancers, exceptions occur in the above-cited lymphomas, where
over half contain recurrent and often multiple Myc point
mutations, which are generally confined to the N-terminal
transcriptional regulatory domain (TRD). These commonly cluster
around Thr58 and Ser62 whose phosphorylation status greatly
affects protein stability, transactivation and transformation [3,4,5].
Less frequent mutations involve an evolutionarily conserved 15–20
residue segment of the TRD known as Myc Box II (MBII)
[6,7,8,9], which contributes importantly to the transforming
function of Myc and is a site of several significant protein-protein
interactions that influence transformation [10,11,12,13]. Burkitt’s
lymphoma-associated point mutations within MBII have been
shown to reduce the ability of Myc to promote apoptosis while
concurrently attenuating its transforming capacity and/or ability
to stimulate growth [14,15,16]. Enhanced survival of Myc
overexpressing cells thus seems to be a property that is highly
selected for during the course of tumor evolution and may be more
important than transformation itself. The exact contribution of
each point mutation to these phenotypes is unclear, however, as
they often occur in the context of other point mutations.
A hallmark of many cancer cells is a high rate of glycolysis, even
in the face of sufficiently high oxygen levels to support oxidative
phosphorylation (OXPHOS). Defined as the ‘‘Warburg effect’’,
this was initially attributed to a functional impairment of
OXPHOS and/or defective mitochondrial biogenesis [17]. More
recently, it has been viewed as allowing a reprogramming of
cellular energy metabolism whereby TCA cycle intermediates can
be redirected toward the enhanced synthesis of the amino acids,
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fatty acids, and nucleotides needed to support the more robust
growth and proliferative demands of the transformed state [18].
Indeed, Myc over-expression actually leads to increased mito-
chondrial biogenesis and the induction of select enzymes of the
TCA pathway [19,20]. As a result of this shift in metabolic
balance, and because the glycolytic pathway is a less efficient ATP
energy source, many transformed cells seem to be extremely
dependent on external glucose supplies (i.e.- they become glucose
‘‘addicted’’)[21]. Consistent with this, many cancer cells express
high levels of glycolytic enzymes [22] and the genes encoding a
number of these are also Myc-regulated [20,23]. It has been
proposed that the ability of Myc to alter metabolism in this
manner is an essential feature of its ability to promote cell cycle
entry [24], although a functional metabolic link to other cellular
behaviors remains to be established. Together, these metabolic
changes may also explain the profound reliance of cancer cells on
exogenous glutamine. Because this amino acid is transported into
the mitochondria and subsequently enters the TCA cycle as
glutamate, it has been proposed that this provides the interme-
diates for and facilitates the generation of biosynthetic pathway
precursors [18,25].
The increased aerobic glycolysis that defines the Warburg effect
emerges gradually and in response to the step-wise activation of
oncogenes and loss of the TP53 tumor suppressor pathway that
contribute to the fully transformed state [26,27]. However, it
remains unclear to what extent this and other metabolic changes
specifically contribute to transformation. Using defined Myc point
mutants that retain only certain Myc functions, we have asked how
the loss of specific phenotypes affects others, particularly those
pertaining to metabolism and transformation. We report here that
many Myc phenotypes, including the Warburg effect and
enhanced OXPHOS, can be genetically uncoupled. Moreover,
none of the specific phenotypes examined are required for
transformation, although they do appear to influence the efficiency
with which transformation occurs.
Results
Expression of Myc point mutants
Previous studies have shown that several naturally-occurring
and synthetic MBII point mutations affect the ability of Myc to
transform and/or promote proliferation and apoptosis. However,
some of these proteins contained multiple TRD mutations, were
assessed only for a limited number of phenotypes, or were
evaluated in different cell types that complicated or precluded
cross-study comparisons [10,14,15,28]. We therefore re-examined
these properties, as well as several additional ones, in the same cell
line for four individual point mutants (Figure 1a). The Q131R and
C133S constructs alter residues that have been targeted in
previous studies [15]. The F138C mutant has been found to
occur naturally in Burkitt’s lymphoma, although it typically
appears in combination with other mutations [5,28]. The
W135E mutant has been identified as having a reduced
transformation capacity [15] and has been speculated to be
deficient it its ability to interact with other proteins such as
TRAAP [29]. These human proteins were expressed in Rat1a
fibroblasts, because this cell background has been routinely used to
evaluate numerous Myc phenotypes, including anchorage-inde-
Figure 1. Expression of Myc mutants in Rat1a cells. (a) Diagram of the Myc protein. The approximately 150 residue TRD is shaded, with an
expanded MBII domain and relevant amino acids substitutions depicted below the diagram. The basic-helix-loop-helix dimerization domain at the
extreme C-terminus of the protein is indicated by the checkered box. (b) Each of the indicated mutations, along with wtMyc was expressed in Rat1a
fibroblasts following lentiviral-mediated transduction. An empty lentiviral vector infection served as a negative control. Pooled, blasticidin-resistant
colonies were subjected to western analysis for either Myc or b-tubulin, which served as a loading control. The monoclonal antibody used to detect
human Myc proteins had some cross reactivity with endogenous rat Myc.
doi:10.1371/journal.pone.0013717.g001
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pendent transformation and in vivo tumorigenesis [14,15,30,31].
Following high-efficiency lentiviral-mediated transduction, surviv-
ing clones were pooled and immediately examined for the
expression of their respective proteins. As seen in Figure 1b, all
four mutants were expressed at similar levels and were comparable
to the expression of the wild-type Myc (wtMyc) protein.
Mutant Myc proteins differentially affect proliferation and
apoptosis
Myc confers a proliferative advantage when over-expressed in
various cell backgrounds including Rat1a cells [32]. We therefore
compared the growth rates of the six Rat1a cell lines depicted in
Figure 1 under non-limiting growth conditions (Figure 2). When
viable, adherent cells were enumerated, it was observed that all
MBII mutants and wtMyc cells grew modestly faster than did the
vector control line. C133S and W135E cells also attained
approximately a 1.5-2-fold higher final density and remained
viable longer. We next asked whether any of the mutations altered
the well-known ability of Myc over-expression to sensitize cells to
pro-apoptotic stimuli [15,33,34,35]. We therefore grew each of the
cell lines to approximately 80% confluency under non-limiting
conditions, then changed to media lacking either serum (Figure 3a)
or glutamine (Figure 3b), and subsequently assessed viability. As
seen in Figure 3a, wtMyc cells showed the expected high sensitivity
to serum deprivation as manifested by an approximately 9-fold
higher fraction of apoptotic cells at 72 hours when compared to
vector cells. W135E and C133S cells were almost as sensitive as
wtMyc cells to serum withdrawal, whereas Q131R cells and
F138C cells, like vector cells, were resistant.
The cell death induced by glutamine withdrawal did not produce
as robust of a response as did serum deprivation, taking
approximately one week to observe significant cell death. Whereas
the control cells were mostly resistant to death under these conditions,
wtMyc, Q131R, C133S and F138C all showed similar ultimate levels
of demise, although the rates of death were somewhat slower for all
the mutants. In contrast, W135E showed a modestly accelerated rate
of apoptosis. From these studies we conclude that Myc mutants are
differentially responsive to serum and glutamine deprivation.
Moreover, while at least two mutants (Q131R and F138C) were
unable to impart a pro-apoptotic response to serum removal, none
entirely abolished the response to glutamine depletion.
Mutant Myc proteins differentially affect genomic
instability
Myc affects genomic stability at multiple levels. For example,
Myc over-expression, particularly when coupled with TP53
dysfunction, can lead to the stochastic accumulation of tetraploid
cells, which are particularly prone to further chromosomal
instability [36,37,38]. Myc deregulation also induces high levels
of ROS, which can induce double-stranded DNA breaks and point
mutations [39,40]. It has been proposed that the potency of Myc
as an oncoprotein originates from its unrelenting assault on
genomic integrity and serves as a driver of tumor cell evolution
[41]. However, the relationships among these processes and those
investigated above have not been formally tested.
To assess the ability of Myc proteins to promote genomic
instability (GI), we first exposed each of the above six cell lines to
colcemid and then quantified the resulting fraction of tetraploid
cells by flow cytometry. As seen in Figure 4a, vector cells routinely
arrested in G2/M following short-term exposure to the drug
whereas a substantial fraction of wtMyc cells became tetraploid
[37,38]. C133S, W135E, and F138C cells recapitulated this to
varying degrees, whereas Q131R cells failed to show any evidence
of tetraploid formation.
Figure 2. Effect of Myc point mutations on proliferation. The indicated Rat1a cell lines were seeded at 104 cells/well in 12 well plates and
allowed to attach in medium containing 10% FBS. At the indicated times, the total cell number in triplicate wells was determined. The points shown
represent the average number of cells/well +/2 1 standard error (SE). The experiment was repeated on at least three occasions with similar results.
Only adherent cells were counted. The number of cells at the latter time points may be affected by contact inhibition or cell loss due to overgrowth.
doi:10.1371/journal.pone.0013717.g002
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We next quantified ROS production in these cells using the
fluorescent activation of CM-H2-DCFDA as a surrogate marker
[39,40,42]. As expected [40,42], wtMyc cells showed significantly
higher baseline levels of ROS than did vector cells. In contrast,
only C133S cells were able to generate comparable levels of ROS
(Figure 4b). From these and the foregoing studies, we conclude
that Myc mutations differentially affect tetraploidy and ROS
induction and that these two properties are genetically separable.
Real-time assessment of OXPHOS and glycolysis
An XF24 Extracellular Flux Analyzer (Seahorse Bioscience) was
used to obtain real-time determinations of parameters pertaining
to OXPHOS and glycolysis. OXPHOS is represented by the
oxygen consumption rate (OCR) [43], which is expressed as pmol
per minute as oxygen undergoes a four-electron reduction to water
at complex IV. As represented in Figure 5a, and as subsequently
confirmed in multiple experiments, baseline OCR (measured
between 0–25 min) was consistently 10 fold higher in wtMyc cells
than in vector control cells. These results confirmed previous
reports documenting Myc-mediated enhancement of OXPHOS
[24,44,45,46]. In three cases (C133S, W135E, and F138C) the
baseline OCRs were between those of wtMyc and vector control
cells, suggesting that these mutations reduced, but did not
eliminate, the increase in OXPHOS. In contrast, baseline OCR
for Q131R cells was identical to that of vector control cells.
Following these initial determinations, all cell lines were
sequentially and simultaneously exposed to four different inhibitors
to yield a profile of bio-energetic capacity. Oligomycin (injection 1)
prevents the flow of protons from the mitochondrial intermembrane
space back into the matrix through complex V. This causes a
buildup of protons and a subsequent decrease in the ability of
electrons to flow down the electron transport chain. The result is a
large decrease in OCR and is indicative of marked inhibition of
OXPHOS (Figure 5a). Cyanide p-trifluoromethoxy-phenylhydra-
zone (FCCP; injection 2) causes protons on the outside of the inner
mitochondrial membrane to be carried across to the basic matrix,
allowing both electron flow to be re-established and oxygen
consumption to resume at levels equal to or exceeding those of the
original baseline despite the persistent oligomycin-induced block of
complex V. This is believed to be a measure of ‘‘spare respiration
capacity (sRC)’’ [47,48]. Following FCCP injection, wtMyc cells
showed the largest sRC whereas vector control cells andQ131R cells
showed the smallest. The remaining three Myc mutant cell lines
showed intermediate sRCs. 2-deoxy-D-glucose (2-DG) was then
added to inhibit glycolysis (injection 3). In all cell lines, this resulted in
a further increase in OCR. This increase, in combination with the
sRC, represents the ‘‘total reserve respiratory capacity’’ (tRRC) of
the cell [47,48]. wtMyc displayed the largest tRRC, which was 10-
fold higher than vector control cells. All Myc mutants had
comparatively less tRRC, and only F138C was significantly elevated
relative to the control (Figure 5b). Finally, the injection of rotenone
(injection 4), which inhibits complex I, resulted in the complete
cessation of electron flow and oxygen consumption in all cell lines.
Concurrently measured with OCR was the extracellular
acidification rate (ECAR), expressed as mpH units per minute,
which is a measure of the glycolytic conversion of glucose to
lactate. Basal ECARs for wtMyc cells were approximately 7-fold
higher when compared to vector control cells (Figure 5c, 0–
25 min), supporting previous studies showing that Myc over-
expression increases glycolysis as well as OXPHOS [24]. All four
Myc mutants displayed reduced ECARs. Three to five replicate
experiments showed that none of the baseline ECAR values were
significantly different from vector control cell values.
As had been done for OCR, ECAR was measured as the
previously described pharmacologic inhibitors were added. All cell
lines showed an increase in ECAR as glycolysis became the major
energy source following the poisoning of OXPHOS by oligomycin
(injection 1) and the resumption of electron flow following the
addition of FCCP (injection 2). The area under the curve between
these two injection points represents a measure of glycolytic
potential [47,48] and only wtMyc cells showed elevated ECAR
relative to vector control cells at this stage (2.2 fold difference,
Figure 3. Cell death mediated by Myc proteins. The indicated Rat1a cell lines were seeded into 12 well pates at 105 cells/well and allowed to
achieve approximately 80% confluency. At the indicated times, viable cell numbers in triplicate plates were determined by flow cytometry using an
Annexin V-Propidium Iodide staining protocol as described in Materials and Methods. The results represent the average amount of staining for the
triplicate samples +/2 1 SE. The experiment was repeated on at least three occasions with similar results. (a) Serum withdrawal. The cells were
washed in PBS and incubated in serum-free medium for the remainder of the study. (b) Glutamine withdrawal. The cells were washed in PBS and
incubated in glutamine-free medium for the remainder of the study.
doi:10.1371/journal.pone.0013717.g003
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Figure 5d). Upon the resumption of electron flow and oxygen
consumption following FCCP addition (injection 2), all cell lines
showed a reduction in ECAR values, which underwent the
expected further decline following the addition of 2-DG (injection
3). From these studies, we conclude that the Myc mutants,
particularly Q131R, were all compromised with respect to their
ability to increase OXPHOS and glycolysis but that in all cases,
each pathway retained the ability to respond in an appropriate and
reciprocal manner upon inhibition of the other pathway.
Mutant Myc proteins retain competency for
transformation
Given that each of the four mutantMyc proteins was in some way
defective for one or more Myc phenotypes, we next asked how they
affected transformation. We were particularly interested in Q131R,
which was most restricted in its ability to confer any of the non-
transforming Myc phenotypes thus far examined. As seen in
Figure 6a, three of the point mutant cell lines (Q131R, W135E, and
F138C) showed a modest to moderate (approximately 30–70%)
reduction in anchorage-independent clonogenic growth compared
to wtMyc cells whereas C133S cells were somewhat more efficient.
These findings were corroborated in tumor xenograft assays, which
showed that all of the mutant cell lines were capable of tumorigenic
growth, although lag times were prolonged and did not correlate
well with in vitro clonogenicity assays (Figure 6b). Most notably,
tumors arising from the inoculation of Q131R cells grew at rates
indistinguishable from those formed by wtMyc cells.
In vivo measurement of tumor metabolism
To determine whether the metabolic defects described above may
have been confined only to the in vitro setting, we used positron
emissions tomography to compare the uptake of 18F-2-DG in tumor
xenografts arising fromwtMyc, Q131R and F138C cells. As shown in
Figure 7 the latter tumors were only slightly less metabolically active
than the former. From these studies, we conclude that the decrease in
metabolic up-regulation seen in Q131R and F138C cells is a
consistent finding that is independent of the tumor cell environment.
Discussion
Myc deregulation in many cell types, including Rat1a
fibroblasts, affects multiple phenotypes, including proliferation,
Figure 4. GI induced by Myc proteins. (a) Induction of tetraploidy. Each of the depicted cell lines showed indistinguishable cell cycle parameters
during logarithmic growth in the absence of colcemid (top row). Treatment of vector cells with colcemid resulted in the expected accumulation of
G2/M-arrest cells containing a 4N DNA content, whereas a significant fraction of wtMyc cells accumulated tetraploid DNA content (8N bottom row)
[28,58]. Note the varying degrees of tetraploidy induction in all mutant cell lines except Q131R. (b) Induction of ROS. Each of the cell lines was
exposed to CM-H2-DCFDA and was then assessed by flow cytometry. Note the .3-fold higher levels of ROS in wtMyc cells compared to vector
control cells as previously described [33,39] and that only C133S cells were able to reproduce this effect. p-values were calculated by a two-tailed t-
test in Microsoft Excel when compared to vector cells: (*) p#0.05; (**) p#0.005.
doi:10.1371/journal.pone.0013717.g004
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apoptosis, and GI [14,15,16,19]. More recently, Myc deregulation
has been implicated in altering cellular metabolism, particularly by
inducing both the Warburg effect and a reliance on exogenous
glutamine [18,25,49]. Although these properties are likely
intertwined with transformation at some level, their individual
contributions remain largely unknown. Previous work, however,
has shown that some of these phenotypes can be severely
compromised without exerting significant effects on transforma-
tion. For example, cells expressing certain Burkitt’s lymphoma-
associated point mutants are more resistant to pro-apoptotic
stimuli and less responsive to proliferative signals than are those
expressing wtMyc [14,15,16]. This has suggested that such
mutants are selected for because they impart a relative survival
advantage even if they are transformation deficient [10,14,15]. We
have characterized a set of Myc mutants in an attempt to better
define the roles of the various phenotypes on tumor growth. We
individually mutated four residues (Q131, C133, W135, and
F138), which have been previously shown either to occur naturally
(albeit rarely) in Burkitt’s lymphomas and/or to interfere in
experimental systems with the transformation potential of Myc or
its ability to interact with transcriptional co-regulators
[5,12,15,28,42]. This represents the first study in which mutants
of this type have been investigated for their ability to influence
metabolism. We have chosen to express these mutants in Rat1a
fibroblasts as they have been repeatedly used to assay a variety of
phenotypes including cell transformation following only the over-
expression of wtMyc [14,15,30,31], and therefore represent the
only system in which the specific effects on these various
phenotypes could be thoroughly studied in an isogenic back-
ground.
Increased OXPHOS has been shown to be important for cell
cycle entry and is commonly linked to transformation [24].
Figure 5. OCR and ECAR in Rat1a cells expressing human Myc point mutants. (a) A Seahorse Bioscience XF24 Extracellular Flux Analyzer
was used for the real-time determination of metabolism. OCR (OXPHOS) was expressed as a function of time. Each inhibitor as described in Results
was injected at the times indicated by the vertical lines (injections 1–4). A typical experiment, performed in triplicate wells is shown. The experiment
was repeated on at least three occasions with similar results. (b) Areas under the curve (AUC) were calculated with the software provided by the
manufacturer and used to compare the various cell lines’ total reserve respiratory capacity relative to that of vector control cells, which are arbitrarily
set at 1. The average of three to five individual experiments, where each cell line was measured at least in triplicate is displayed +/2 1 SE. p-values of
the comparisons with vector control cells were calculated by a two-tailed t-test in Microsoft Excel: (*) p#0.05; (**) 0.01. This graph represents the
AUCs for the time point just prior to injection 2 until the time point just before injection 4. This represents the total reserve respiratory capacity of
each cell line. (c) ECARs (glycolysis) were expressed as a function of time. The vertical lines represent the same injections as previously described. The
experiment was repeated on at least three occasions with similar results. (d) AUCs for the time point just prior to injection 1 to the time point just
prior to injection 2 were calculated. This is the best representation of the glycolytic potential of these strains. p-values were calculated and
represented as described for (b).
doi:10.1371/journal.pone.0013717.g005
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Aerobic glycolysis, or the so-called Warburg effect, is also
frequently observed in cancer cells although it is not invariably
associated with transformation. However, it may become more
prominent when the cells are grown as tumors or metabolically
stressed by hypoxia [18,23,24,25,50]. It does appear, however,
that virtually all cancer cells increase their glucose metabolism via
some combination of increased OXPHOS and aerobic glycolysis
[19,50].
The use of pharmacologic agents to inhibit OXPHOS and
glycolysis at various steps indicated that appropriate and reciprocal
changes in the other pathway occurred in each case (Figure 5).
These findings do not support the idea that qualitative defects in
specific TCA cycle enzymatic pathways account for the switch
from OXPHOS to aerobic glycolysis seen in the majority of
cancers [20]. Rather, they are consistent with the notion that the
enhanced metabolism of Myc-deregulated tumor cells is much
more commonly due to increases in the otherwise functionally
normal enzymes comprising these two metabolic pathways
[18,25]. Such quantitative changes would seem to be the best
suited to addressing the demands of the transformed cell for
various TCA cycle-derived anabolic precursors [18,24,51] while
simultaneously providing the flexibility needed to increase
glycolysis in response to the hypoxic tumor microenvironment.
However, our results also indicate that transformation per se
requires neither increased OXPHOS nor induction of the
Warburg effect, although it is possible that these changes
Figure 6. Effect of Myc point mutations on transformation. (a) In vitro transformation. Anchorage-independent clonogenic growth in soft
agar was assessed as previously described [54,56]. 12–14 days after plating, the total number of macroscopically visible colonies on each plate was
quantified. Numbers shown represent the average number of colonies seen in triplicate cultures +/2 1 SE. p-values of the comparisons with vector
control cells were calculated by a two-tailed t-test in Microsoft Excel: (**) p#0.01; (***) #0.005. (b) In vivo transformation. 56106 of the indicated
Rat1a cell lines were inoculated subcutaneously into the flanks of nude mice. Each inoculum was performed in triplicate and tumor sizes were
evaluated weekly. The data shown represents two individually repeated experiments. Averages tumor sizes [52] +/2 1 SE are depicted as a function
of time.
doi:10.1371/journal.pone.0013717.g006
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contribute to the efficiency with which transformed cells can grow
as anchorage-independent colonies or as xenografts in vivo
(Figure 6).
We are unable to say unequivocally that transformation and
glutamine addiction can be dissociated from one another given
that none of the mutants tested entirely relieved the cellular
reliance on glutamine. Our analyses do however, allow us to
conclude that the normal levels of OXPHOS and glycolysis seen
in several of the cell lines are not necessarily associated with
normalization of glutamine dependency. These studies again
suggest these processes are under distinct forms of genetic
regulation as has been shown for other Myc phenotypes [15].
High levels of potentially mutagenic ROS have been proposed
to arise from an increased flux of electrons through the electron
transport chain as a result of the more robust OXPHOS of
transformed cells [20,40]. However, we noted discordance
between ROS production and OXPHOS in three of the four
Myc mutants (Q131R, W135E, and F138C). Indeed, a compar-
ison of C133S and F138C, both of which showed equivalent
reductions in OXPHOS levels relative to wtMyc indicated that
only the former was able to enhance ROS levels in Rat1a cells
(Figure 4b). Taken together, these findings demonstrate that, while
much of the Myc-mediated ROS induction may well have a
mitochondrial origin, a significant fraction appears to originate
elsewhere, perhaps as a consequence of the increased sensitivity of
Myc-regulated proliferation-associated or other signaling pathways
[52]. They also indicate that elevated OXPHOS does not
invariably lead to the generation of high levels of ROS. Additional
studies will be needed to define the mitochondrial and non-
mitochondrial sources of ROS.
In summary, our findings indicate that single point mutations in
of the MBII domain of Myc can genetically uncouple transfor-
mation from several of the phenotypes that contribute to and are
closely associated with the transformed state. Additionally, several
of these phenotypes are genetically separable from each other. The
number and the degree to which these phenotypes are affected are
variable and dependent upon the specific point mutation.
Specifically, the dispensability of these various Myc-regulated
behaviors for transformation was most conspicuously exemplified
by Q131R cells, which were lacking in most of the studied
phenotypes, yet were still able to grow as anchorage-independent
colonies and form tumors at nearly the same rate as wtMyc cells.
The multiple Myc phenotypes examined here, including the
metabolic ones, thus appear to affect the efficiency with which cells
can be transformed but are to a large degree dispensable. Most
significantly, we have shown that these phenotypes include the
Warburg effect and that neither increased aerobic glycolysis nor
particularly elevated OXPHOS are absolutely necessary for
achieving a transformed state.
Materials and Methods
Construction of Myc mutants
All human Myc proteins were expressed in the pLenti-V5-
TOPO-Blast vector (Invitrogen, Inc. Carlsbad, CA) as non-
epitope-tagged full-length proteins. The vector encoding wild-type
Myc was used as a template for oligonucleotide directed point
mutagenesis utilizing a QuickChange II kit according to the
directions of the supplier (Stratagene, Inc. LaJolla CA). All
lentiviral vectors were propagated in the Stbl3 E. coli strain
(Invitrogen) and mutations were confirmed by automated DNA
sequencing.
Cell Culture and lentiviral transductions
All lentiviral work was approved by the University of Pittsburgh
Institutional Biosafety Committee and was performed under
BSL2+ conditions. Lentiviral plasmids were packaged in 293FT
cells (Invitrogen) using vectors supplied with the ViraPower
Expression kit (Invitrogen, San Diego, CA). Viral supernatants
were harvested 48 and 72 hr after transient transfection, filtered
through 0.45 mM nitrocellulose filters (Millipore, Inc., Bedford,
NY) and were used to infect semi-confluent Rat1a fibroblasts
[30,53,54], in the presence of 8 mg/ml Polybrene (Sigma-Aldrich,
St. Louis, MO). After two sequential overnight infections, the
Rat1a cells were incubated for an additional 48 hr before being
split 1:3 and selected in the presence of 2 mg/ml of blasticidin
(Invitrogen). Blasticidin-resistant clones were then pooled and used
in all subsequent studies. We refer to these cell lines according to
the identity of the transduced Myc protein (e.g. wtMyc cells, vector
control cells, Q131R cells, C133S cells, W135E cells, and F138C
cells). Unless otherwise stated, both 293FT cells and Rat1a cells
were propagated in Dulbecco’s-modified minimal essential
medium (D-MEM) containing 10% fetal bovine serum, glutamine,
and penicillin plus streptomycin as previously described [53,55].
Immunoblotting
Lentiviral-transduced Rat1a cells were grown to approximately
90% confluency under standard conditions and were then
harvested with trypsin. After washing twice in PBS, cell pellets
were lysed in SDS-PAGE lysis buffer without b- mercaptoethanol
and protein concentrations were quantified using a BCA protein
determination kit (Pierce, Rockford, IL). 100 mg of total lysate
from each cell line was then resolved on a 10% polyacrylamide gel
and transferred to a PVDF membrane (Millipore) by semi-dry
electroblotting as previously described [30,53]. Immunoblotting
was performed as previously described [42] with a monoclonal
antibodies against c-Myc (9E10; Santa Cruz cat. no. sc-40) and b-
tubulin (Santa Cruz- cat. no. sc-5274) to serve as a loading control.
The blots were developed using a chemiluminesence-based
method as previously described [30,42].
Apoptosis and Proliferation Assays
For apoptosis assays, Rat1a cells were plated in 12 well tissue
culture plates and grown to approximately 80% confluency. They
were then washed twice in serum-free D-MEM and incubated in
the same medium for the remainder of the study. At the beginning
Figure 7. 18F-2DG imaging by PET. Duplicate tumor-bearing mice
inoculated with wtMyc, Q131R, or F138C cells were imaged by PET
following injection of 18F-labeled 2DG. Dotted lines indicate tumor
boundaries. Arrows indicate the urinary bladder, where the isotope is
expectedly the most concentrated. The average relative SUV is
indicated with the value for wtMyc set at 1.
doi:10.1371/journal.pone.0013717.g007
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of the study and at various times thereafter, the cells were
harvested with trypsin and stained with FITC-Annexin V and
propidium iodide using a ApoTargetTM Kit as recommended by
the supplier (Invitrogen). Results were expressed as the mean of
triplicate assays +/2 the standard error (SE). Proliferation assays
were performed in D-MEM containing 10% FBS as previously
described [30,53]. The results of proliferation assays were also
expressed as the mean of triplicate samples +/2 1 SE. All of the
above experiments were repeated at least three times with similar
results.
Measurement of genomic instability
The induction of tetraploidy following the short term exposure
to colcemid was performed as previously described [37,38]. The
quantification of ROS was performed as previously described [39]
except cells were incubated in 1% serum at 37C for 16 hours prior
to staining with 2.5 mM CM-H2-DCFDA (Molecular Probes-
Invitrogen). Cells were subsequently analyzed by flow cytometry
and data is represented as previously described [42]. In brief, the
calculation of ROS was derived by first establishing a consistent
histogram for control cells stained with CM-H2-DCFDA and then
subsequently comparing the experimental flow profiles to that
control. Samples were run in triplicate and experiments were
repeated at least three separate times. Values are expressed as
relative mean values 6 SE.
Measurements of OXPHOS and glycolysis
All measurements were performed with a Seahorse Bioscience
XF24 Extracellular Flux Analyzer (Billirica, MA). Rat1a cell lines
were plated onto Seahorse 24 well plates as recommended by the
manufacturer. Unless otherwise stated, the standard Rat1a cell
concentration was 20,000/well, which were seeded the day before.
Immediately following the addition of fresh medium, basal levels
of O2 consumption and proton production were first quantified
over approximately 20–25 min. The next measurement was
performed during the blockade of complex V by 1 mM oligomycin
(injection 1). This causes a build-up of protons across the inner
mitochondrial matrix with subsequent loss of electron flow. The
addition of cyanide p-trifluoromethoxy-phenylhydrazone (FCCP)
(final concentration 300 nM; injection 2) causes the protons on the
outside of the inner membrane to be carried across to the
mitochondrial matrix. The addition of 2-deoxyglucose (2-DG)
(final concentration 100 mM; injection 3) inhibits glucose uptake
into glycolysis and the TCA cycle. Finally, the injection of
rotenone (final concentration 1 mM; injection 4) inhibits complex
I, leading to cessation of both electron flow and oxygen
consumption. Experiments were performed by simultaneously
measuring three to five replicates of each cell line. Four of the six
cell lines could be measured in a single experiment. Relative effects
were expressed as areas under the curve measurements that were
generated by the manufacturer’s software and used to compare the
various cell lines.
Measurement of cellular transformation
Soft agar assays were used to measure in vitro transformation
capacity of Rat1a cells expressing various Myc proteins [12,30,56].
Tumor studies were performed by subcutaneously injecting the
flanks of nude mice with 56106 of the indicated Rat1a cell lines
[56,57]. Tumor volumes were calculated using the formula: K6
L6W6H [58].
Positron emission tomography (PET)
Tumor-bearing mice were injected with approximately 250 mCi
18F-2-deoxyglucose (18F-2-DG) via the tail vein twenty minutes
prior to imaging with a PET scanner. Mice were anesthetized with
isofluorane during the procedure. Standardized uptake values
(SUVs) were calculated for each tumor.
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